Arpida Annual General Meeting of Shareholders Approves All Board... ( REINACH Switzerland May 7 /- The ...)

Arpida Annual General Meeting of Shareholders Approves All Board Proposals

Date:5/7/2009

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors.

A total of 90 shareholders were present at the meeting that took place in Reinach today. 4,629,711 shares were represented, or 21.9% of the total number of shares issued (21,094,104).

The following items were on the agenda.

1. Information on strategic options

There was a lively discussion regarding the possible strategic scenarios as presented by the CEO, Dr Jurgen Raths. An overview of these scenarios was already published in a press release earlier today. Shareholders provided valuable comments that will be incorporated in the further strategic evaluation. No decision was taken yet. The Board of Directors assured the shareholders that they will be duly involved in any major strategic decision.

2. Approval of the 2008 Business Report, Company Accounts and Group Accounts

The shareholders approved the 2008 Business Report, comprising the annual financial statements, the consolidated accounts and the 2008 Annual Report.

3. Discharge of the Board of Directors and of the Senior Executive Officers

The shareholders granted discharge to the Board of Directors and to the Senior Executive Officers for their actions.

4. Compensation of Losses with General Reserves

The shareholders approved the Board proposal to compensate the accumulated loss of CHF 189,591,477 with an equal amount of share premium in the general reserves.

5. Re-election of the Auditors

The shareholders re-elected PricewaterhouseCoopers Ltd as Auditors for 2009.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-
'/>"/>

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 17, 2013) A million electric cars could be on ... with the help of research by the United States Department ... Waterloo. , Professor Zhongwei Chen is part of a team ... non-precious materials to replace the expensive platinum catalysts in fuel ... of fuel cells in vehicles is the cost of the ...

(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...

(Date:6/18/2013)... In support of Swiss contributions to ... of Switzerland in New York is pleased to welcome ... PlanetSolar , to Manhattan. PlanetSolar is in New ... tour with scientists on board from the University of ... exclusively on energy from the sun and eliminates the ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... Inc.,(NASDAQ: ISOT ) ("IsoTis"), an orthobiologics company, today ... it called to approve,the acquisition of IsoTis by Integra ... an agreement and plan of merger,dated as of August ... held at 9 a.m. Pacific time,today. An insufficient number ...

... Oct. 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... for 2007 after the market closes on Tuesday, November ... 4:30 p.m. EST,1:30 p.m. PST, on the company,s website. ... to the Company,s website at, http://www.cvt.com and go ...

... to be initiated by end of 2007 -, ... BIIB ) and PDL BioPharma, Inc. (PDL) (Nasdaq: ... a significant reduction in new or,enlarged gadolinium-enhancing lesions when ... active relapsing multiple,sclerosis (MS). These data will be presented ...

Cached Biology Technology:IsoTis Adjourns Special Meeting to October 23, 2007 2 IsoTis Adjourns Special Meeting to October 23, 2007 3 IsoTis Adjourns Special Meeting to October 23, 2007 4 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6

IsoTis Adjourns Special Meeting to October 23, 2007 CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy

(Date:6/18/2013)... , June 19, 2013 Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...

(Date:6/18/2013)... at the University of Calgary,s Faculty of Medicine have ... body from harmful bacteria. Platelets, a component of blood ... for specific bacteria, and upon detection, seal it off ... were published in Nature Immunology this week, ... immunity. , "The science community has known that platelets ...

(Date:6/18/2013)... Researchers from the United Kingdom, the Energy Department,s ... of Kentucky have recently published a paper describing ... borer Limnoria quadripunctata , commonly known as ... because they exhibit a relatively unique ability to ... microbes to break down the biomass they eat. ...

Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2 Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3 Immunity mechanism discovered 2 Novel enzyme from tiny gribble could prove a boon for biofuels research 2

[0] Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show [0] Immunity mechanism discovered [0] Novel enzyme from tiny gribble could prove a boon for biofuels research

... the growing demand from the public and the scientific ... Press has revised its copyright policy to allow authors ... three journals. The policy, which became effective May 1, ... Journal of Cell Biology, The Journal of Experimental Medicine ...

... the human genome has been sequenced, research into mechanism of ... most human genes have not been isolated. This is true ... protein kinases, which mediate the majority of signaling events in ... It has been estimated by systematic gene sequencing efforts that ...

... which he calls a "smarthroscope", may be able to ... could be useful in developing countries. It aims ... the tissue surrounding an area affected by illnesses such ... and bone damage. The instrument would also help ...

Cached Biology News:Rockefeller University Press allows authors to retain copyright to their published work 2 QUT researchers develop smart instrument for tissue damage assessment 2

Rockefeller University Press allows authors to retain copyright to their published work Researchers report the cloning of a key group of human genes, the protein kinases QUT researchers develop smart instrument for tissue damage assessment

... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...

... The reliable and compact GC-8A is ... applications. Economical and simple to use, the ... or flow control, on column injection port(s), ... ramp program models are available. The GC-8A ...

... system combines world-class performance hardware, Cerity Networked ... world-renowned support and columns, as well as ... that lets you reach uncompromising results and ... data. The Agilent 6820 GC system is ...

... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...

Biology Products:

LTQ XL with ETD from Thermo Scientific GC-8 Gas Chromatograph from Shimadzu 6820 GC from Agilent Technologies 7890A GC from Agilent Technologies